Literature DB >> 33475833

Clinical impact of preoperative tumour contact with superior mesenteric-portal vein in patients with resectable pancreatic head cancer.

Fabio Ausania1, Santiago Sanchez-Cabus1, Paula Senra Del Rio2, Alex Borin3, Juan Ramon Ayuso4, Pilar Bodenlle5, Sofia Espinoza1, Miriam Cuatrecasas6, Carlos Conill7, Tamara Saurí8, Joana Ferrer1, Josep Fuster1, Juan Carlos García-Valdecasas1, Reyes Melendez2, Constantino Fondevila1.   

Abstract

INTRODUCTION: The NCCN classification of resectability in pancreatic head cancer does not consider preoperative radiological tumour ≤ 180° contact with portal vein/superior mesenteric vein (PV/SMV) as a negative prognostic feature. The aim of this study is to evaluate whether this factor is associated with higher rate of incomplete resection and poorer survival.
METHODS: All patients considered for pancreatic resection between 2012 and 2017 at two Spanish referral centres were included. Patients with borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC) according to NCCN classification were excluded. Preoperative CT scans were reviewed by dedicated radiologists to identify radiologic tumour contact with PV/SMV.
RESULTS: Out of 302, 71 patients were finally included in this study. Twenty-two (31%) patients showed tumour-PV/SMV contact (group 1) and 49 (69%) did not show any contact (group 2). Patients in group 1 showed a statistically significantly higher rate of R1 and R1-direct margins compared with group 2 (95 vs 28% and 77 vs 10%) and lower median survival (24 vs 41 months, p = 0.02). Preoperative contact with PV/SMV, lymph node metastases, R1-direct margin and NO adjuvant chemotherapy were significantly associated with disease-specific survival at multivariate analysis.
CONCLUSION: Preoperative radiological tumour contact with PV/SMV in patients with NCCN resectable PDAC is associated with high rate of pathologic positive margins following surgery and poorer survival.

Entities:  

Keywords:  Pancreatectomy; Pancreatic cancer; Prognostic factors; Surgical margins

Year:  2021        PMID: 33475833     DOI: 10.1007/s00423-020-02065-w

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  3 in total

1.  Prehabilitation in patients undergoing pancreaticoduodenectomy: a randomized controlled trial.

Authors:  Fabio Ausania; Paula Senra; Reyes Meléndez; Regina Caballeiro; Rubén Ouviña; Enrique Casal-Núñez
Journal:  Rev Esp Enferm Dig       Date:  2019-08       Impact factor: 2.086

Review 2.  Meta-analysis of recurrence pattern after resection for pancreatic cancer.

Authors:  M Tanaka; A L Mihaljevic; P Probst; M Heckler; U Klaiber; U Heger; M W Büchler; T Hackert
Journal:  Br J Surg       Date:  2019-08-27       Impact factor: 6.939

Review 3.  Imaging of pancreatic adenocarcinoma: update on staging/resectability.

Authors:  Eric P Tamm; Aparna Balachandran; Priya R Bhosale; Matthew H Katz; Jason B Fleming; Jeffrey H Lee; Gauri R Varadhachary
Journal:  Radiol Clin North Am       Date:  2012-04-06       Impact factor: 2.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.